## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `pt-141-chemo-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `pt-141-chemo-neuropathy` v2 · content_hash `7b873ec00dff3804…` · thread_head genesis · 22 DIVs
- **thesis (c1):** No human clinical trials have tested PT-141 for CIPN.
  - c2 [human/active] A 2024 meta-analysis found limited and inconsistent evidence for gabapentinoids in CIPN prevention and treatment.
  - c3 [mechanistic/active] PT-141 acts as a melanocortin receptor agonist primarily affecting central arousal pathways.
  - c4 [mechanistic/active] Gabapentin/pregabalin suppresses neuropathic pain signals without repairing nerves.
  - c5 [anecdotal/active] Reddit anecdotes mention PT-141 in neuropathy contexts only in passing and note its sexual-arousal focus rather than pain relief.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `pt-141-chemo-neuropathy`
- **title:** PT-141 for Chemotherapy-Induced Neuropathy: Evidence Review
- **url:** https://miscsubjects.com/a/pt-141-chemo-neuropathy
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:04.767Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)

Chemotherapy-induced peripheral neuropathy develops when certain chemo agents damage peripheral nerves. Sensory fibers often suffer first, producing numbness, tingling, burning pain, or loss of sensation in hands and feet. Motor involvement can follow with weakness or balance issues. Autonomic nerves may also be affected. The core process is axon degeneration and demyelination that outpaces natural repair mechanisms. Once nerves are damaged, symptoms can persist months or years after treatment ends. No approved therapy reverses the underlying nerve injury; management focuses on symptom control.

## Why PT-141 might help you

1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.
2. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts primarily in the central nervous system on pathways linked to arousal and desire. If your CIPN includes central sensitization or sexual function disruption from nerve damage, the compound's CNS effects are the relevant layer. No data connect melanocortin activation to peripheral nerve regeneration or axon repair in CIPN. The logic chain stops at the known mechanism: central arousal signaling, not peripheral tissue repair.

## Why Gabapentin / pregabalin matters for you

**Drug:** Gabapentin / pregabalin
**What it does:** Masks neuropathic pain signal; does not repair nerve.
**Therefore for you:** This drug suppresses a signal. It can reduce pain perception and improve sleep or daily function while the underlying nerve damage remains. Symptom relief may lower overall stress on the nervous system but trades off any direct support for repair pathways. Evidence for CIPN is limited and inconsistent.

## How these fit together

Single-compound focus — PT-141 addresses sexual / CNS arousal pathways. Gabapentin or pregabalin addresses pain signal suppression. They target separate layers with no overlapping repair mechanism described in available sources. Any combined use would require separate evaluation of each layer's contribution to your symptoms.

## What the evidence actually shows

No human clinical trials have tested PT-141 or bremelanotide in CIPN patients (tier: human - none). No rat or mouse studies of PT-141 in chemotherapy neuropathy models appear in indexed literature (tier: preclinical - none). All discussion of PT-141 in this context remains mechanistic or speculative based on its established use in hypoactive sexual desire disorder.

Gabapentinoids show limited evidence in CIPN. A 2024 meta-analysis found pregabalin did not significantly prevent CIPN on average pain scores and yielded inconsistent results for treatment (tier: human). ASCO guidelines note that gabapentin or pregabalin may be considered for positive sensory symptoms but with limited scientific evidence of benefit.

## What scientists say

Researchers describe PT-141 as a central melanocortin agonist approved for sexual desire disorders. No publications link it to neuroprotection, axon regeneration, or CIPN models. Neuropathy experts emphasize the absence of disease-modifying agents for CIPN and the reliance on symptomatic drugs with modest, variable effects.

## What people say on Reddit

Anecdotal posts rarely mention PT-141 in CIPN contexts. One user in a small-fiber neuropathy thread noted trying PT-141 among other peptides but attributed any improvement to different compounds and explicitly stated PT-141 is oriented toward sexual arousal rather than pain reduction (tier: anecdotal). Other threads discuss PT-141 for post-cancer sexual dysfunction without reference to neuropathy symptoms.

## What people say on X

No relevant public posts linking PT-141 to CIPN or chemotherapy neuropathy were identified in available searches.

## What we do not know

Whether melanocortin agonism could influence nerve repair pathways in humans with CIPN is unknown. No dose-response, safety, or efficacy data exist for this use. Long-term effects on damaged peripheral nerves remain unstudied.

## Safety and limits

PT-141 carries known side effects including nausea, flushing, and blood-pressure changes from its approved use. Gabapentinoids can cause dizziness, sedation, and require dose adjustment in some patients. Both approaches address symptoms or specific CNS functions rather than reversing chemotherapy-induced nerve damage. Readers should consult qualified clinicians for individualized assessment; this review contains no treatment recommendations.

## Claims (5)

- **c2** [human w=0.8] A 2024 meta-analysis found limited and inconsistent evidence for gabapentinoids in CIPN prevention and treatment.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c4** [mechanistic w=0.3] Gabapentin/pregabalin suppresses neuropathic pain signals without repairing nerves.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c1** [human w=0.8] No human clinical trials have tested PT-141 for CIPN.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c3** [mechanistic w=0.3] PT-141 acts as a melanocortin receptor agonist primarily affecting central arousal pathways.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c5** [anecdotal w=0.3] Reddit anecdotes mention PT-141 in neuropathy contexts only in passing and note its sexual-arousal focus rather than pain relief.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `dfbd76cb8ad6b18d`

### s1 · review · ok
- title: Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/
- summary: Review of bremelanotide mechanism and approval data; no mention of neuropathy applications.
- quote: Bremelanotide (PT-141) is a melanocortinergic agent, demonstrated efficacy in improving male and female sexual dysfunction
- claim_ids: c1
- hash: `0c022fc538f1de85`

### s2 · pubmed · ok
- title: Gabapentinoids for chemotherapy-induced peripheral neuropathy
- url: https://pubmed.ncbi.nlm.nih.gov/38936970/
- summary: 2024 meta-analysis showing inconsistent results for gabapentinoids in CIPN.
- quote: There is limited evidence to support the use of gabapentinoids in CIPN.
- claim_ids: c2, c4
- hash: `990c858f5c6e823b`

### s3 · review · http_403
- title: Bremelanotide: Uses, Interactions, Mechanism of Action
- url: https://go.drugbank.com/drugs/DB11653
- summary: Confirms central melanocortin mechanism.
- quote: Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women.
- claim_ids: c3
- hash: `0d11326ee0e7f15a`

### s4 · reddit · ok
- title: Effectiveness of ARA-290...My Assessment
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/v44s3q/effectiveness_of_ara290my_assessment/
- summary: User comment distinguishing PT-141 from pain-focused peptides.
- quote: PT-141 is more sexual/arousal. Wouldn’t recommend that if your focus is on pain reduction.
- claim_ids: c5
- hash: `dfbd76cb8ad6b18d`

## Provenance (2 model passes)
- chain valid: yes · head: `9800b2ce322032f1`

- write · grok/grok-4.3 · 2026-06-30T01:20 · hash `02b14ca9275d`
- voxel_divide · owner · 2026-07-17T02:41 · hash `9800b2ce3220`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"pt-141-chemo-neuropathy","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest pt-141-chemo-neuropathy|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim pt-141-chemo-neuropathy|tier|assertion`
- **iMessage ask:** `pt-141-chemo-neuropathy|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `pt-141-chemo-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/pt-141-chemo-neuropathy/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*